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Abstract: The aim of this paper is to investigate the most critical parameters determining radiotherapy treatment outcome 
in terms of tumor cell kill for glioblastoma multiforme tumors by using an already developed simulation model of in vivo 
tumor response to radiotherapy.  
INTRODUCTION  
  Radiation therapy plays a central role in the management 
of cancer. Radiation is considered now a well understood 
cytotoxic agent [1: pg. 7]. Apart from advances in the so-
called physical treatment planning, which refers to tech-
niques used for improving radiation dosimetry and dose dis-
tribution, it is now widely recognized that further improve-
ments in radiotherapy treatment will most probably require 
increasing grounding in fundamental radiobiological mecha-
nisms [1].  
  Cancer biology plays a critical role in determining radio-
therapy treatment outcome. In this context, efficient model-
ing of tumor response to radiotherapy can contribute to the 
elucidation of the involved biological mechanisms and to the 
emergence of patient-individualized treatments, on the pre-
supposition of adequate clinical adaptation and testing. 
  During the last years researchers have enhanced the un-
derstanding of tumor behavior by means of various simula-
tion models. Representative examples drawn from the exten-
sive corresponding literature have been given in [2]. Analyti-
cal mathematical models are valuable tools to study some 
aspects of tumor radiobiology. Discrete time algorithmic 
descriptions (computer simulations) present the advantage of 
great adaptability in treating complex situations. They offer 
the possibility of accounting for a large number of mecha-
nisms and interactions and they are therefore particularly 
suitable to describe in vivo tumor growth and response to 
irradiation. The stochastic nature of the involved biological 
phenomena favors the choice of stochastic techniques such 
as the generic Monte Carlo method for oncological simula-
tions. An extensive presentation of computer simulation 
models of particular interest has been given in [3].  
  The goal of this study was an investigation of the relative 
impact of the most critical parameters determining radiother- 
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apy treatment outcome in terms of tumor cell kill for 
glioblastoma multiforme (GBM) tumors by performing ade-
quate simulations using an already developed simulation 
model of in vivo GBM response to radiotherapy. For each of 
the selected critical parameters a series of simulation runs 
covering the whole range of values that have appeared in the 
literature for GBM have been performed, while adjusting the 
remaining parameters at the most typical GBM values. GBM 
is a highly aggressive type of brain tumor. Prognosis for pa-
tients with GBM remains dismal despite efforts to improve 
current therapies and develop novel clinical approaches [4].  
  The comparison of the simulation results with clinical 
experience and experimental knowledge was selected as a 
means to reveal and substantiate the potential and flexibility 
of the particular simulation model in order to study biologi-
cal phenomena related to cancer and in the long-term serve 
as a patient individualized treatment optimization tool, fol-
lowing a strict clinical validation procedure. 
MATERIALS AND METHODOLOGY 
Brief Outline of the Simulation Model  
 The  In Silico Oncology Group (ISOG) simulation model 
of imageable GBM response to radiotherapy, which has been 
used for the purposes of this study, is based on the clinical, 
imaging, histopathologic, and molecular data of the patient 
and incorporates numerous fundamental biological mecha-
nisms. The model is characterized by the combination of the 
following features: (i) possibility for simulation of both un-
treated in vivo tumor growth and in vivo tumor response to 
radiotherapy; (ii) possibility for consideration and use of the 
actual imaging, histopathologic and molecular data for each 
particular clinical case (clinical orientation); (iii) incorpora-
tion of numerous biological mechanisms by means of an 
explicit algorithmical description; (iv) introduction of the 
notion of the ‘‘geometrical cell’’ and its constituent com-
partments, called ‘‘equivalence classes’’, corresponding to 
discrete phases within or out of the cell cycle; (v) extensive 
use of random number generators to simulate the stochastic 
nature of various biological phenomena involved (Monte 
Carlo approach); (vi) discrete and modular character, which 
confers a high level of adaptability; (vii) possibility for 3D 44    The Open Biomedical Engineering Journal, 2008, Volume 2  Dionysiou et al. 
reconstruction and visualization of the results. A detailed 
description of the simulation model can be found in [2, 3, 5]. 
For the sake of clarity and completeness of information re-
garding the methods used in this work a brief outline of the 
model is presented below.  
  The clinician delineates the tumor and its inner regions of 
interest by using a dedicated computer tool. For GBM, high 
signal intensity in T1-weighted contrast-enhanced MRI with 
gadolinium corresponds to regions of actively proliferating 
tumor cells, while low intensity regions correspond to ne-
crotic regions [4: pg. 109]. A 1mm-thick layer surrounding 
the necrotic region is assumed to correspond to the resting 
cells’ region. The distribution of the absorbed dose in the 
region of interest according to the treatment plan is also ac-
quired.  
  A prototype system of quantizing cell clusters included 
within each elementary cubic volume of a discretizing mesh 
covering the anatomic area of interest lies at the heart of the 
simulation approach. During a simulation the geometrical 
mesh is scanned with a time step of an hour. The elementary 
cubic volume of the mesh is called “Geometrical Cell (GC)”. 
In each time step, the updated state of a given GC is deter-
mined on the basis of a number of algorithms describing the 
behavior of the cells constituting the tumor. More specifi-
cally, each GC of the mesh belonging to the tumor contains 
cells, which are distributed in a number of “classes” (com-
partments), each one characterized by the phase in which its 
cells are found (within or out of the cell cycle: G1, S, G2, M, 
G0, Necrosis, Apoptosis). Specially designed stochastic cel-
lular automata describe tumor cell kinetics, by incorporating 
the following biological phenomena: 
•  Cycling of proliferating cells through the subsequent 
phases of the cell cycle. 
•  Spontaneous apoptosis. 
•  Transition to a dormant (G0) phase due to inadequate 
supply with oxygen and nutrients. 
•  Local reoxygenation and nutrient provision reestablish-
ment. 
•  Cell death through necrosis due to prolonged oxygen 
and nutrients deprivation.  
•  Radiotherapy-induced cell death: possibility of distinc-
tion between two mechanisms of radiation-induced cell 
death, namely apoptotic and necrotic cell death.  
•  Apoptotic cell death can be furthermore subdivided into 
radiation-induced interphase death (direct death through 
apoptosis) and radiation-induced mitotic apoptotic death. 
In most solid tumors, though, the majority of lethally 
damaged cells dies through a radiation-induced mitotic 
necrotic mechanism and is considered to undergo a few 
mitotic divisions prior to death and disappearance from 
the tumor (two mitotic divisions assumed in the current 
version of the simulation model) [1, 6].  
•  The probability of cell death taking place through each 
specific mechanism depends primarily on cell type [7, 
8]. 
  Cell killing by irradiation is described by the Linear 
Quadratic or LQ Model, which is widely used in the perti-
nent literature [1]:  
S(D)=exp[-(D+D
2)    …             (1) 
where S(D) is the surviving fraction after a (uniform) dose D 
(Gy) of radiation to a population of cells. The parameters  
(alpha) (Gy
-1) and  (beta) (Gy
-2) are called the radiosensitiv-
ity parameters of the LQ model. Cell radiosensitivity varies 
considerably throughout the cell cycle [1, 9, 10]. The S 
phase is regarded as the most resistant. Cells in any prolifer-
ating phase are more radiosensitive than hypoxic cells resid-
ing in G0. Based on these observations the model currently 
uses different values for the radiosensitivity parameters of 
the LQ model for the S phase (s,s), the remaining prolifer-
ating phases G1, G2, M (p,p), and the G0 phase (G0, G0). 
The values of s , s and G0, G0 can be derived as perturba-
tions of the (p,p) values, as for example in: G0= p /OER, 
G0= p /OER
2, s = 0.6 p + 0.4G0, s = 0.6p + 0.4G0, 
where OER is the Oxygen Enhancement Ratio [9]. 
  Tumor expansion or shrinkage is simulated on the basis 
of the following algorithms: If the number of tumor cells 
contained within a given GC drops below a given threshold, 
then a procedure which attempts to “unload” the remaining 
cells in the neighboring GCs takes place. Cells are preferen-
tially placed within the neighboring GCs with the maximum 
available free space. If the given GC becomes empty, it is 
assumed to disappear from the tumor, in which case an ap-
propriate shift of a chain of GCs, intended to fill the “vac-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). A simplified flow diagram of the simulation model. 
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uum”, leads to tumor shrinkage. This can happen after the 
killing of a number of cells by irradiation. On the other hand, 
if the number of alive and dead cells within a given GC ex-
ceeds a given threshold, then a similar procedure attempting 
to unload the excess cells in the surrounding GCs takes 
place. In case that the unloading procedure fails to suffi-
ciently reduce the number of cells, then a new GC emerges. 
Its position relative to the “mother” GC is determined using 
a random number generator. An appropriate shifting of a 
chain of adjacent GCs leads to a differential expansion of the 
tumor.  
  A simplified flow diagram of the simulation model is 
depicted in Fig. (1). 
RESULTS 
Literature Review  
  A thorough study of glioblastoma multiforme literature 
preceded the simulations, so as to define the real clinical 
range of the values of various model parameters. The pa-
rameters selected for the study of their relative impact in 
GBM’s response, based on accumulated clinical and experi-
mental knowledge, were the  and  radiosensitivity parame-
ters of the LQ model, the cell cycle duration (TC), the cell 
loss factor (CLF) and the growth fraction (GF) of the tumor. 
These constitute three parameters characterizing the kinetic 
behavior of tumors (TC, CLF, GF) and two parameters ( 
Table 1.   Values of Cell Cycle Duration for GBM Cell Lines/Tumors 
TC (hours)  Reference  Source 
36-48 [11]  Literature  review 
26.2±5.6  [12]  U87 cell line, 4 surgical specimens 
24-48  [13]  13 surgical specimens 
22  [14]  U251 cell line 
75.6±45.7  [15]  24 glioma surgical specimens (of which 13 GBMs) 
48-72 [16]  - 
57±6  [17]  4 surgical specimens 
Table 2.  Values of the  and  Parameters of the Linear Quadratic Model for GBM Cell Lines 
 (Gy
-1)   (Gy
-2) Reference Cell  line 
0.05 0.05 [10]  U87MG   
0.1 0.06 [10]  SF-126   
0.31 0.04 [10]  SF-268   
0.36 0.06 [10]  U-251MG   
0.45 0.06 [10]  SF-188   
0.61 0.02 [10]  U87-LUX.8 
0.17 0.02 [10]  U87-175.4 
0.167±0.052 0.021±0.003 [20] GB  A7(puro) 
0.370±0.077 0.015±0.007 [20]  GB  A7R 
0.25(0.22-0.29) -  [21]  HGL21   
0.32(0.28-0.36) -  [21]  D54MG   
0.387±0.121 -  [22] U87MG   
0.226±0.023 -  [22] U373MG 
0.482±0.055 -  [22]  M059J 
0.038±0.004 0.007±0.002 [23]  U87MG   
0.05±0.007 0.018±0.003 [23]  T98G   
0.031 0.0030  [24]  U251 
0.017 0.019  [24]  U87 
0.058 0.0061  [24]  T98G 46    The Open Biomedical Engineering Journal, 2008, Volume 2  Dionysiou et al. 
and ) widely used to describe tumor cell radiosensitivity. 
These parameters reflect characteristics of a tumor that are 
determined largely by the underlying genetic profile of the 
tumor cells. 
 More  specifically,  Table  1 presents the values reported in 
the literature for the cell cycle duration of GBM cell lines, 
xenografts or primary tumor specimens. The corresponding 
references are [11, 12-17]. The distribution of the total cell 
cycle duration to the various phases constituting the cell cy-
cle (G1, S, G2, M) has been assumed to follow the distribu-
tion in a typical malignant cell as described in [18]: 
G1TC40%, S TC39%, G2TC19%, M TC2%.  
  It should be noted that different distributions of cell cycle 
phase durations have been also encountered in the relevant 
literature. Many authors state that the varying length of G1 
phase accounts for most of the differences reported in the 
total cell cycle duration between different cell types or be-
tween cells growing under different conditions, while S and 
M phases are normally quite fixed in duration [19]. A com-
parative study of the effect of the adoption of this alternative 
assumption has been also performed. 
 Table  2 presents the results of the literature search for 
values of the  and  parameters of the LQ model for GBM, 
which are generally considered to reflect tumor cell intrinsic 
radiosensitivity. The corresponding references are [10, 20-
24]. Cellular sensitivity to irradiation reflects a culmination 
of numerous molecular pathways including DNA repair and 
cell cycle checkpoint fidelity. 
 Table  3 presents the values found in the literature for the 
cell loss factor of GBM, which is defined as the cell loss rate 
as a fraction of the cell birth rate [1, 13]. The corresponding 
references are [25-28]. The concept of the cell loss factor 
emphasizes that a tumor is a dynamic system and that its net 
growth is the cumulative effect of competing processes of 
cell proliferation, death and removal. The simulation model 
considers necrosis and apoptosis as the basic mechanisms of 
cell loss and assumes that the total cell loss factor is the sum 
of the cell loss factor due to necrosis and the cell loss factor 
due to apoptosis. Furthermore, in the particular case of GBM 
the contribution of necrosis to the total cell loss is considered 
far more important than that of apoptosis (necrosis 10-fold 
higher), as gliomas exhibit in general low levels of spontan-
teous or radiation-induced apoptotic cells [29-31]. It should 
also be noted that cell loss factor values are considered fixed 
throughout radiotherapy in the simulation model. This is also 
a reasonable first approximation for tumors that exhibit little 
or no regression in post-irradiation imaging studies, such as 
Table 3.  Values of the Cell Loss Factor for GBM Tumors 
CLF Reference  Source 
0.278  [25]  5 U87 xenografts in nude mice 
0.17 
0.49 
[26] 
U87, HGL9 and 
U251-MG xenografts in nude mice 
0.171 
0.45 
0.272 
0.11 
0.16 
0.555 
[27]  HGL9, HGL21, HGL29, U251-MG, MMC1, U87 and Hp56 xenografts in nude mice 
0.75 
0.32 
0.13 
0.44 
0.04 
0.37 
[28]  15 ethylnitrosourea-induced rat gliomas 
 
Table 4.  Values of the Growth Fraction for GBM Tumors 
GF (%)  Reference  Source 
28 (14-4)  [11]  From literature review 
8-46  [13]  13 surgical specimens 
Approximately 15  [15]  24 glioma surgical specimens (of which 13 GBMs) 
10-30 [16]  - 
14-39 (31±10)  [17]  4 surgical specimens 
10-40  [33]  22 surgical specimens  A Computer Simulation  The Open Biomedical Engineering Journal, 2008, Volume 2    47 
GBM [10]. This is thought to happen in cases where the 
blood flow to the tumor does not change during therapy and 
is usually observed for very slow growing tumors or those 
that have low cell loss factors at initiation of treatment, such 
as GBM [6, 32]. 
 Finally,  Table  4 presents the values found in the literature 
for the growth fraction of GBM tumours, i.e. the fraction of 
actively cycling tumor cells. The corresponding references 
are [11, 13, 15-17, 33]. 
SIMULATION RESULTS  
  For each of the selected critical parameters a series of 
simulation runs covering the whole range of values that have 
been reported in the literature for GBM have been per-
formed, while adjusting the remaining parameters at the 
most typical GBM values. For example, typical parameter 
values for GBM are: TC = 40h [11], =0.36Gy
-1, =0.02Gy
-2 
[10, 34], CLF=0.3 [25], GF=25% [11]. The duration of the 
G0 phase has been adjusted to 25h [35] and the oxygen en-
hancement ratio has been taken equal to 3 [36, 37]. The ini-
tial tumor was a typical case of a 34.55cm
3 GBM delineated 
based on MRI imaging data. The initial tumor volume corre-
sponds to a total of 34550 GCs of 1mm
3 each. Assuming a 
typical cell density of 10
6cells/mm
3 [1:9-10] this corresponds 
to an initial number of cells equal to 3.45510
10 (or ap-
proximately 10gr). The outer boundary of the tumor and a 
central necrotic area were evident on the T1 imaging data, 
while an intermediate region with increased percentage of 
G0 cells has been assumed to surround the necrotic area in 
accordance with general biological knowledge. A central 
slice of the tumor is depicted in Fig. (2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). A central MRI slice of the tumor that has been considered 
as a typical GBM case. A specialist has delineated the outer bound-
ary of the tumor (yellow) and the central necrotic area (green) with 
the use of a specially developed computer tool. A 1mm-thick layer 
surrounding the necrotic region is assumed to correspond to the 
resting cells’ region. 
 
 Figs.  (3-8) depict the simulation results in the form of the 
number of living tumor cells as a function of time. The time 
point t=0 corresponds to the start of the radiotherapy treat-
ment. The standard fractionation scheme of 2Gy/day, 5 
days/week, 60Gy in total, no irradiation during weekends, 
was used in all simulation cases.  
 
 
 
 
 
 
 
 
 
 
Fig. (3). Number of living tumor cells as a function of time from 
the start of radiotherapy treatment (at t=0), for hypothetical GBM 
tumors differing in the value of the alpha parameter of the LQ 
model.  is in Gy
-1. 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Number of living tumor cells as a function of time from 
the start of radiotherapy treatment (at t=0), for hypothetical GBM 
tumors differing in the value of the beta parameter of the LQ model. 
 is in Gy
-2. 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Number of living tumor cells as a function of time from 
the start of radiotherapy treatment (at t=0), for hypothetical GBM 
tumors differing in the value of the cell cycle duration. 
 
  According to the results obtained for the parameter 
ranges considered, the parameters with the major impact on 
the tumor’s response to radiotherapy were the alpha parame-48    The Open Biomedical Engineering Journal, 2008, Volume 2  Dionysiou et al. 
ter of the LQ model and the cell cycle duration of tumor 
cells, while the effect of the other parameters was less pro-
nounced. More specifically, starting with an otherwise iden-
tical tumor in all cases, by varying the values of the alpha 
parameter the resulting number of living tumor cells one 
week after the end of treatment (t=6 weeks) spans an interval 
of approximately 10 orders of magnitude (logs). The corre-
sponding interval in the cases of TC, beta, CLF and GF pa-
rameters is approximately of the order of 7, 2, 1.5 and 0.5 
logs correspondingly. 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Number of living tumor cells as a function of time from 
the start of radiotherapy treatment (at t=0), for hypothetical GBM 
tumors with (A): C = 40h and cell cycle phase durations according 
to [18] (G1:16h, S:15h, G2:8h, M:1h), (): C = 50h and cell cycle 
phase durations according to [18] (G1:20h, S:19h, G2:10h, M:1h), 
(C):  C =50h and G1 phase duration 10h longer than in (A) 
(G1:26h, S:15h, G2:8h, M:1h). 
 
  In Fig. (6) the effect of adopting the two alternative dis-
tributions for the cell cycle phase durations that have been 
discussed above, is depicted by means of a comparative 
simulation. More specifically, the values of TC=40h and 
TC=50h are considered for this exploratory simulations. The 
consideration of TC equal to 50h by attributing the extra 
duration compared to TC=40h in the G1 phase (G1:26h, 
S:15h, G2:8h, M:1h), instead of distributing the extra time in 
all phases according to [18] (G1:20h, S:19h, G2:10h, M:1h), 
seems to enhance the tumor cell kill effect, since G1 has 
been assumed as a relatively radiosensitive phase of the cell 
cycle.  
 
 
 
 
 
 
 
 
 
 
Fig. (7). Number of living tumor cells as a function of time from 
the start of radiotherapy treatment (at t=0), for hypothetical GBM 
tumors differing in the value of the cell loss factor. 
DISCUSSION  
  The critical importance of the alpha parameter of the LQ 
model and of the cell cycle duration as major determinants of 
tumor response to radiotherapy is well documented in rele-
vant literature [1:242, 38]. The cell cycle duration is directly 
linked to tumor cell proliferation during treatment. Rapidly 
proliferating tumors might be expected to repopulate more 
rapidly during treatment and thus be relatively resistant to 
some forms of treatment. Of course the proliferative poten-
tial of a tumor apart from the cell cycle time depends on the 
growth fraction and on the cell loss rate as well. 
  The linear component in the LQ model ( coefficient) is 
related to the initial slope of the survival curve and is 
thought to be due to single-track events. The quadratic com-
ponent ( coefficient) is related to the slope of the survival 
curve at higher doses, and is considered to reflect sub-lethal 
damage repair. The ratio / is the dose for which the contri-
bution of the linear and the quadratic terms are equal and is 
descriptive of the rate of the survival curve’s bending, with 
smaller values corresponding to higher rates. Clinically rele-
vant radiation doses (around 2Gy, as in standard radiother-
apy treatment for GBM) are generally dominated by the al-
pha component of the clonogenic survival curve, to which 
differences between radiosensitive and radioresistant cells 
are mainly attributed. For such dose fractions, the beta pa-
rameter seems to present little variation between different 
cells [1: pg. 190, 9: pg. 23-24, 91-95, 10, 38]. 
  For example, in [39] the effect of radiosensitivity on tu-
mor response to radiotherapy was examined by varying al-
pha from 0.2 to 0.35 to 0.5Gy
-1 with / fixed at 10Gy. The 
model assumed that the bulk tumor was composed of viable 
cells and “doomed” cells and used a modified LQ model to 
compute “doomed” cells for a typical tumor of 5.8cm diame-
ter (100gr), irradiated by a radiotherapy treatment of 30 frac-
tions of 2Gy, given at a rate of 5 fractions per week (a frac-
tion is delivered every 1.4days). The LQ model modification 
refers to the integration into the model of a description of 
tumor cell proliferation, whereby the tumor grows exponen-
tially when its size is below a threshold value and in Gom-
pertzian mode when its size is greater than the threshold. The 
tumor cell population is assumed homogeneous in terms of 
radiosensitivity.  
  The author of this study concludes that radiosensitivity 
has a very significant effect on the nadir of the surviving 
fraction. The depth of nadir of the surviving fraction in-
creases with increasing radiosensitivity. The survival frac-
tion interval at the end of treatment is approximately 9.5logs. 
This could be considered a rather good agreement with the 
results produced in our study taking into account the differ-
ences in the underlying simulation models. Furthermore after 
a parameter sensitivity analysis performed by considering 
1% changes in the values of the model parameters, the 
author reaches the conclusion that radiosensitivity was, by 
far, the most dominant parameter, followed by proliferation 
rate and doomed cell loss rate, which is also in agreement 
with the results presented here. 
  On the other hand, the small contribution of the beta ef-
fect to the overall radiosensitivity of a tumour has been fre-
quently reported in the literature [1: pg. 190, 9: pg. 24].  A Computer Simulation  The Open Biomedical Engineering Journal, 2008, Volume 2    49 
  As far as the variation in the growth fraction of GBM 
tumors is concerned, it is observed from Fig. (8) that, as ex-
pected, as time increases the absolute difference between the 
numbers of surviving cells is constantly decreasing. There-
fore, it is becoming progressively easier for the curves corre-
sponding to different growth fractions to coincide at certain 
points if the stochasticity of the mathematical treatment is 
taken into account. It is obvious that after a point at which 
the number of surviving cells of two initially different tu-
mors becomes the same their further relative time course is 
random given that the same treatment scheme is applied. It 
should be noted that different values of the growth fraction 
are computed in the model by appropriately adjusting the 
number of dead cells so as to have the same total number of 
cells (i.e. the hypoxic fraction remains the same). 
 
 
 
 
 
 
 
 
 
 
Fig. (8). Number of living tumor cells as a function of time from 
the start of radiotherapy treatment (at t=0), for hypothetical GBM 
tumors differing in their growth fraction. 
 
  To summarize, the relative impact on GBM response to 
standard radiotherapy treatment of three major parameters 
characterizing the kinetic behaviour of tumors (TC, GF, 
CLF) and two parameters widely used to describe radiosensi-
tivity ( and  parameters of the LQ model) has been studied 
by means of comparative simulations with the help of a four-
dimensional (in time and space) computer simulation model. 
A thorough literature review to investigate the real clinical 
ranges of these parameters for GBM tumors has been per-
formed. According to the simulation results obtained, the 
parameters with the major impact on the tumor’s response to 
radiotherapy were the  parameter of the LQ model and the 
cell cycle duration of tumor cells, while the effect of the 
other parameters was less pronounced. In general, the simu-
lation results are supported by clinical experience and repro-
duce the dismal prognosis for GBM in terms of tumor cell 
kill. Clinical reality has been reproduced in the sense that for 
almost all combinations of parameter values (apart from 
=0.61Gy
-1) reported in the literature for GBM, the standard 
radiotherapy treatment seems to be inadequate to kill all tu-
mor cells that have been initially assumed for a 10gr-tumor. 
  It should be stressed that the values of these parameters 
that have been derived from literature reflect the specific 
molecular profiles of the cell lines or tumors for which they 
are computed, and thereby provide a means to reflect into the 
simulation model the effect of various genetic determinants 
of tumor response to radiotherapy. For example, using the 
values of the alpha and beta parameters found in [10], which 
refer to two isogenic cell lines differing only in their p53 
status and performing comparative simulations, the influence 
of p53 gene status can be reflected in the simulations results, 
as has been performed in [5]. 
  It should also be noted that as first approximation tumor 
cell heterogeneity in terms of cell cycle time or intrinsic ra-
diosensitivity in the same cell cycle phase has not been taken 
into account. In addition, in the current version of the model 
all proliferating cells are assumed to be clonogenic; cells of 
limited proliferative potential or terminally differentiated 
cells are ignored. This is a logical first approximation for 
GBM which is a poorly differentiated tumor [25, 40]. 
Moreover, differentiated cells are generally not a danger to 
the patient, although their bulk contributes to the tumor vol-
ume. Nevertheless, versions of the model incorporating the 
distinction between stem cells, cells of limited proliferative 
potential and terminally differentiated cells are under prepa-
ration. 
  A further note of concern is the accuracy of the experi-
mental values used in the simulation, which depends on the 
model system and the experimental procedure used for the 
measurement in the corresponding studies from which they 
were derived. Several causes of discrepancies between pa-
rameter values computed for established cell lines or tumor 
xenografts and real clinical tumors have been frequently re-
ported in the literature [20, 26, 38, 41]. For example, estab-
lished cancer cell lines some times exhibit different charac-
teristics compared to in vivo tumors mainly as a result of the 
controlled environment of the experiments or the genetic 
drift observed over time. 
CONCLUSIONS 
  Notwithstanding the uncertainties and simplifications 
mentioned in previous paragraphs, since the simulation re-
sults generally reproduce clinical reality, they thereby sub-
stantiate the clinical potential, the flexibility and the robust-
ness of the simulation model, especially in view of its clini-
cally oriented design. Its usefulness for gaining insight into 
critical biological mechanisms seems straightforward. From 
a wider perspective, the models’ translation into the clinical 
environment in order to serve as a patient individualized 
treatment optimization tool, following a strict validation pro-
cedure based on clinical data, can be envisaged. A similar 
process of clinical translation of computer simulation models 
of the ISOG group for the case of chemotherapy treatment of 
breast cancer and Wilms’ tumors is currently under way in 
the framework of the EC funded project “ACGT: Advancing 
Clinicogenomic Trials on Cancer” (FP6-2005-IST-026996).  
  A simplified case study which could characteristically 
explain the potential of the model to be used as a radiother-
apy treatment optimization tool could be the following: 
1.The imaging, histopathological and molecular data of the 
patient are collected. 2.The patient's imaging tumor data is 
used in order to three dimensionally reconstruct the macro-
scopic structure of the tumor and its metabolic regions of 
interest (well oxygenated, poorly oxygenated and badly oxy-
genated regions). 3.The patient's histopathological and mo-
lecular tumor data are preprocessed in order to estimate the 
patient individualized alpha and beta parameters of the linear 
quadratic model. 4.A number of candidate dose fraction-
ations are simulated for the patient specific virtual tumor. 50    The Open Biomedical Engineering Journal, 2008, Volume 2  Dionysiou et al. 
5.The level of normal tissue complications for each candi-
date schedule is calculated based on standard radiobiological 
techniques. 6.The fractionations which do not lead to normal 
tissue complications beyond the corresponding limits are 
selected. 7. The fractionation that computationally leads to 
the maximum tumor shrinkage (and minimum tumor viabil-
ity) is the theoretically optimal scheme. 8.Provided that pro-
spective and retrospective clinical studies agree with the 
theoretical outcome for the subpopulation in which the pa-
tient falls and that the clinician does not have any substanti-
ated objections, the theoretically suggested treatment sched-
ule may be applied to the patient. 
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ABBREVIATIONS 
CLF  =  Cell Loss Factor of the tumor 
G0  =  Dormant cell cycle phase 
G1  =  G1(Gap 1) cell cycle phase 
G2  =  G2 (Gap2) cell cycle phase 
GBM =  Glioblastoma  Multiforme 
GC =  Geometrical  Cell 
GF  =  Growth Fraction of the tumor. 
ISOG =  In Silico Oncology Group 
LQ Model  =  Linear-Quadratic Model 
M  =  Mitosis cell cycle phase 
NGCT  =  Neighbour GCs belonging to the Tumor 
OER =  Oxygen  Enhancement  Ratio 
S  =  DNA synthesis cell cycle phase 
TC  =  cell cycle duration  
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